{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shao N"],"funding":["the Guangzhou Science and Technology Plan Project","Basic and Applied Basic Research Foundation of Guangdong Province","the Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University, China","National Natural Science Foundation of China","the Medical Joint Fund of Jinan University"],"pagination":["772"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11657429"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["Background
Radiotherapy (RT) is a primary clinical approach for cancer treatment, but its efficacy is often hindered by various challenges, especially radiation resistance, which greatly compromises the therapeutic effectiveness of RT. Mitochondria, central to cellular energy metabolism and regulation of cell death, play a critical role in mechanisms of radioresistance. In this context, cuproptosis, a novel copper-induced mitochondria-respiratory-dependent cell death pathway, offers a promising avenue for radiosensitization.Results
In this study, an innovative theranostic nanoplatform was designed to induce cuproptosis in synergy with low-dose radiation therapy (LDRT, i.e., 0.5-2 Gy) for the treatment of in situ hepatocellular carcinoma (HCC). This approach aims to reverse "],"journal":["Journal of nanobiotechnology"],"pubmed_title":["Synergistic enhancement of low-dose radiation therapy via cuproptosis and metabolic reprogramming for radiosensitization in in situ hepatocellular carcinoma."],"pmcid":["PMC11657429"],"funding_grant_id":["YXJC2022008","2023A1515012660","82171893","JNU1AF-CFTP-2022-a01233","2023A03J1037","82271943"],"pubmed_authors":["Luo Q","Yang Y","Huang Y","Chen J","Hu G","Xiao Z","Zhang H","Luo L","Shao N","Cheng N"],"additional_accession":[]},"is_claimable":false,"name":"Synergistic enhancement of low-dose radiation therapy via cuproptosis and metabolic reprogramming for radiosensitization in in situ hepatocellular carcinoma.","description":"Background
Radiotherapy (RT) is a primary clinical approach for cancer treatment, but its efficacy is often hindered by various challenges, especially radiation resistance, which greatly compromises the therapeutic effectiveness of RT. Mitochondria, central to cellular energy metabolism and regulation of cell death, play a critical role in mechanisms of radioresistance. In this context, cuproptosis, a novel copper-induced mitochondria-respiratory-dependent cell death pathway, offers a promising avenue for radiosensitization.Results
In this study, an innovative theranostic nanoplatform was designed to induce cuproptosis in synergy with low-dose radiation therapy (LDRT, i.e., 0.5-2 Gy) for the treatment of in situ hepatocellular carcinoma (HCC). This approach aims to reverse ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-03T23:13:20.956Z","creation":"2025-04-03T23:13:20.956Z"},"accession":"S-EPMC11657429","cross_references":{"pubmed":["39696547"],"doi":["10.1186/s12951-024-03011-4"]}}